BreastNursingOBGYN & Women's HealthHematology & OncologySurgeryPathologyRadiologyPharmacyBreast CancerCancerChemotherapyHealth TechnologyGenetics
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Oct. 27, 2017 (HealthDay News) -- The 70-gene signature (GS) assay affects treatment decisions among physicians treating patients identified as being at intermediate risk with the 21-gene assay (21-GA), according to a study published online Oct. 26 in JAMA Oncology.
Michaela Tsai, M.D., from the Virginia Piper Cancer Center in Minneapolis, and colleagues conducted a study involving 840 patients with early-stage breast cancer and a 21-gene assay recurrence score of 18 to 30. Physicians were given the 70-GS result before adjuvant treatment, and the change in physician treatment decision was assessed before versus after receiving the result.
The researchers found that receiving the 70-GS classifications was correlated with a significant change in adjuvant treatment decision, with an odds ratio of 0.64 for all patients. Overall, 28.9 percent of low-risk patients had chemotherapy removed from the treatment recommendation, while 36.7 percent of high-risk patients had chemotherapy added. Results of the 70-GS were associated with the physician's adjuvant treatment recommendation; 87.8 percent of high-risk and 90.6 percent of low-risk patients were recommended to receive adjuvant chemotherapy or no chemotherapy, respectively. In 78.6 percent of cases, physicians reported having more confidence in their treatment recommendations based on 70-GS results.
"The 70-GS provides clinically actionable information regarding patients classified as intermediate risk by the 21-GA and was associated with a change in treatment decision in 282 of these patients (33.6 percent)," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Agendia Inc., which funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 29, 2022
Read this Next
Other Trending Articles